NGeneBio
SOLIDaccuTest DNA (84 genes) and RNA (29 genes)
NGS panel of solid tumors: 84 DNA genes and 29 RNA genes for selecting targeted therapy
SOLIDaccuTest combines a DNA panel of 84 genes and an RNA panel of 29 genes for the NGS diagnosis of solid tumors and the selection of targeted therapy.
Request a quotationThe next-generation sequencing panels include 84 genes in the DNA panel and 29 genes in the RNA panel, which are important in lung, stomach, colon, breast and ovarian cancer. The RNA panel further detects fused transcripts. The test results are formed in 3 to 3.5 days and used to select targeted therapies.
The SOLIDaccuTest DNA and RNA panels cover genes clinically relevant to solid tumors; the duration of the analysis is 3-3.5 days.
Panel coverage
- The DNA panel includes 84 genes significant for lung, stomach, colon, breast and ovarian cancers.
- RNA panel of 29 genes reveals fused transcripts characteristic of these tumors
Clinical challenge
- The panel is focused on clinically significant options used to select targeted therapy.
Time limit for implementation
- The result is formed in 3-3.5 days
DNA panel
| Parameter | SOLIDaccuTest DNA/RNA |
|---|---|
| Genes | 84 (cancer of the lung, stomach, colon, breast, ovaries) |
RNA panel
| Parameter | SOLIDaccuTest DNA/RNA |
|---|---|
| Genes | 29 (merged transcripts) |
Time limit for implementation
| Parameter | SOLIDaccuTest DNA/RNA |
|---|---|
| Time frame for analysis | 3–3.5 days |